

Received: 2020-04-24  
Accepted: 2020-08-13  
Published: 2021-00-00

# COMPARING EFFECTIVENESS OF STANDARD VS HF10 SPINAL CORD STIMULATOR IMPLANTS FOR CHRONIC INTRACTABLE PAIN

Manasi Parikh, MS<sup>1</sup>  
Ashish Bhandari, MBBS<sup>2</sup>  
Christopher Gilligan, MD<sup>2</sup>

**Background:** There is limited real-world evidence regarding the long-term effectiveness and safety outcomes related to spinal cord stimulation (SCS) for patients with chronic refractory pain.

**Case Report:** This study included a total of 132 patients (73 had HF10); 53% was female. Mean Pretrial Numeric Pain Score for all patients was  $8.4 \pm 1.1$  which decreased to  $4.4 \pm 2.0$  at the end of one year ( $P < 0.0001$ ). A 6% decrease in the percent of responders, between one month and one-year post-implant, was noted in the HF10 SCS compared to the 15% in standard SCS. A statistically significant decrease in pain relief in the male population ( $P = 0.02$ ) and obese patients ( $P = 0.002$ ) was observed. Most common complications: "IPG malfunction" (17%) for standard SCS and "IPG site pain" (12%) for HF10 SCS.

**Conclusion:** HF10 SCS is a viable alternative to standard SCS for chronic intractable pain conditions.

**Key words:** Complications, HF10, high-frequency stimulation, neuromodulation, patient outcomes, spinal cord stimulation

## BACKGROUND

Chronic pain is a multidimensional health condition defined by the International Association for the Study of Pain (IASP) as pain persisting for more than 6 months (1); it affects 22% of the world population according to a multicenter study conducted by the World Health Organization (WHO) (2). Spinal cord stimulation (SCS) has become a viable treatment option for patients with chronic pain (3,4). SCS patients report greater improvements in pain, quality of life, and activity levels, and have a higher return-to-work rate than those receiving conservative treatment such as pharmacological treatment, physical therapy, epidural injections, and/or radiofrequency therapy (5-7). One important advantage of this intervention is its success in treating chronic non-

malignant pain conditions that previously had limited surgical or pharmacological solutions aside from opioid therapy (8). It is important to report on SCS efficacy over time, given the increasing popularity of this treatment, the initial high costs associated with it, and the expanding range of indications for its use (7,9). Continuous evaluation regarding patient outcomes in terms of pain control, any complications, and overall satisfaction is important in determining SCS's role in clinical practice.

Conventional SCS devices use electrical stimulation, which typically ranges between tens to hundreds of hertz (Hz), and patients perceive nonpainful paresthesia (a stimulation-induced sensation, such as tingling or buzzing) in lieu of otherwise painful sensations. However, standard SCS therapy poses some limita-

From: <sup>1</sup>Graduate Medical Sciences, Boston University School of Medicine, Boston University, Boston, MA; <sup>2</sup>Department of Anesthesiology, Perioperative and Pain Medicine, Brigham & Women's Hospital, Boston, MA

Corresponding Author: Manasi Parikh, MS E-mail: drmanasi.parikh@gmail.com

Disclaimer: There was no external funding in the preparation of this manuscript.

Conflict of interest: Each author certifies that he or she, or a member of his or her immediate family, has no commercial association (i.e., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted manuscript.

tions due to the side effects of paresthesia, such as unintended, unwanted, or painful stimulation, or stimulation shocks because of change in body position (3,10,11). In contrast, the recent clinical use of high-frequency SCS at 10 kHz (HF10™ Therapy by Nevro's Senza SCS system, Rewood City, CA) represents novel neurostimulation therapy. HF10 therapy is the only SCS therapy indicated to provide pain relief without paresthesia and is also the first SCS therapy to demonstrate superiority to traditional SCS for back and leg pain in a few studies (12-15).

However, there is scarce real-world evidence outside controlled study settings in the research literature regarding the use of HF10 SCS. Clinically, there is a lack of high-quality randomized trials with HF10 SCS and, as noted by Song et al (8) in their review, large randomized controlled trials demonstrating clear clinical benefit are needed to gain evidence-based support for their use. Studies have demonstrated the efficacy of SCS using endpoints of pain control as measured by patient-reported pain scores, opioid use, and patient satisfaction (16-18). Despite the vast literature on SCS as a treatment option, there is a relative paucity of literature regarding the correlation between basic demographic data and SCS therapy outcomes.

Currently, there is ambiguity in the literature regarding long-term effectiveness and safety outcomes related to SCS especially given the continuous evolving technology in the field. It is necessary to identify patient outcomes in terms of pain control, demographic data, and overall satisfaction to best classify SCS's role in the pain treatment algorithm and to improve patient education prior to implantation. This study is a comprehensive analysis of patients from one academic center who underwent an SCS implant, with the following objectives: a) describe and compare patient outcomes among patients who underwent standard SCS vs HF10 SCS therapy for treatment of chronic pain in routine clinical practice; b) evaluate any associations between outcomes and basic demographic variables such as age, gender, and weight; and c) identify contemporary incidence of treatment-limiting complications, defined as those requiring a revision or explant.

## **METHODS**

This study was a retrospective, observational analysis of 132 patients who underwent an SCS implant over a 2-year period between September 2015 and September 2017 at Brigham and Women Hospital's

Pain Center. We compared patient outcomes on traditional/standard SCS devices (like Medtronic and Boston Scientific) to the HF10 SCS system (Nevro's Senza SCS system). The academic center has experience in traditional SCS devices as well as the HF10 SCS system since the latter therapy received Food and Drug Administration (FDA) approval in May 2015. Institutional Review Board approval was obtained prior to beginning this study.

## **Study Population and Patient Selection**

All consecutive adult patients diagnosed with a chronic pain condition who underwent permanent, primary cervical or thoracolumbar SCS implantation between September 2015 and September 2017 were included in this study. Patients who had a previous history of SCS implantation and who underwent peripheral nerve stimulation implants at any time during the study period were excluded in this study analysis. Patients were deemed suitable for SCS therapy per physicians' opinion and psychological evaluation.

## **Procedures and Follow-Up**

All patients included in this study had undergone a successful SCS trial prior to implantation and the surgical implant procedure was conducted according to the established standard of care. A 5- to 7-day outpatient trial with an external SCS device was done to determine clinical efficacy. A trial was considered successful if > 50% pain relief was achieved without any adverse effects. After a successful trial, patients proceeded to a permanent SCS implant as a day surgery procedure. The HF10 SCS surgical procedure differs from that used for standard SCS in 3 key technical ways: 1) the 2 leads were sited solely anatomically along the spinal vertebrae; 2) concordant paresthesia-mapping was not performed at any time; and 3) there was no need to lighten sedation for paresthesia testing (15). A programming algorithm was used to optimize the SCS stimulation according to each patient's report of pain relief. Each device was programmed with the aid of a device manufacturer representative to ensure adequate pain relief according to the individual patient's pain distribution. After implantation, follow-up consisted of an initial postoperation visit within 7 days of surgery. This was followed by a one-month visit and then visits as needed for any programming adjustments or complication issues. Changes in pain medications based on clinical judg-

ment and adjustment of stimulation parameters were made throughout the follow-up period. Also, patients could adjust the amplitude of the therapy, within a predefined range, using a patient remote control. Follow-up data was collected through August 2018, allowing for a minimum follow-up time of 12 months since implant or until device explant.

### Data Collection

Patients' baseline, preimplant, and postimplant data were retrieved retrospectively from the site's electronic medical record system. For each patient, the following demographic information was recorded at baseline: age at the time of implantation, gender, body mass index (BMI) at the time of implantation, and date of implantation. SCS vendors included Boston Scientific, Medtronic, and Nevro. Preimplant information included a) indication for implantation, b) percent pain relief during SCS trial, and c) Numeric Pain Score (NPS) (which ranges from 0-10) prior to implant. The NPS was noted from the most recent clinical note prior to implantation. Postimplant information consisted of a) NPS assessed at one month, 6 months, and 12 months post implant as available in the medical records; b) patient satisfaction, determined based on clinical documentation (a patient was recorded as "satisfied" if he or she stated being happy with his or her SCS and felt that undergoing the implantation had improved pain control); c) explant or revision of SCS at any time during the study period and the underlying cause of it; and d) complications related to SCS as reported in the chart during the study period.

### Statistical Analysis

The data was entered in Microsoft Excel (Seattle, WA) and analyzed using R Version 3.5.1 (The R foundation for Statistical Computing Platform, Vienna, Austria). Descriptive statistics were calculated for each analyzed variable and consisted of frequencies, means, percentages, and standard deviation. Two-tailed paired t tests were used to analyze change in the mean percent pain relief as well as change in NPS over time within the same group. The t test (2-tailed) was also used to analyze the statistical significance of the differences in mean percent pain relief among different subgroups. Additionally, the one-way analysis of variance (ANOVA) test was used to compare the mean percent pain relief in the 3 BMI subgroups. A *P* value < .05 was considered as statistically significant.

## RESULTS

### Baseline

A total of 132 patients underwent implant; 47% were men and 53% women. Out of 132, 73 had HF10 SCS implantation, which includes 55% of the total study population. The mean age was 55.6 years. The mean pretrial NPS for all patients was  $8.4 \pm 1.1$  and 50% of the study population fell within the NPS 8-9 range at baseline. According to BMI, patients were further categorized into the following: normal (24%), overweight (35%), and obese (33%). The most common chronic pain condition indication seen in the study population included postlaminectomy syndrome (PLS) (62%), lumbar radiculopathy (LR) or cervical radiculopathy (CR) (12%), and chronic regional pain syndrome (CRPS) (7%). Overall, 79.5% of the study population was satisfied with SCS therapy. Of the patients with HF10 SCS, 80.2% were satisfied compared to 81.3% on standard SCS. A summary of baseline information as well as follow-up is presented in Table 1 and Appendix Fig. 1, respectively.

### Pain Score and Percent Changes in Pain Relief

At one year, the mean reported NPS score for whole study population was  $4.9 \pm 2.1$ , compared with  $4.7 \pm 2.0$  at one month and  $4.7 \pm 2.9$  at 6 months (Table 2). Pain reductions for these patients were statistically significant at one month, 6 months, and one year post implant (*P* < .001). This study shows that the pain relief afforded by SCS is maintained for at least 12 months. The mean percent pain relief during the trial for the study population was 68%, which declined to 41% at the end of one year in the same patient cohort (Fig. 1). The mean percent pain relief was slightly better with standard SCS (70% to 44%; *P* = .30) compared to HF10 (67% to 40%; *P* = .56) over time. As shown in Fig. 2, the mean percent pain relief did not differ much among age groups at the end of one year. In terms of gender, mean percent pain relief was greater among women (43%) compared to men (38%) at one year post implant. Moreover, the decrease in mean percent pain relief for men at one month (44%) as compared to one year (38%) is statistically significant (*P* = .02). The mean percent pain relief increased for normal (40% to 43%; *P* = .73) and overweight patients (43% to 44%; *P* = .69) with time; however, for obese patients it decreased with time (47% to 36%). In the obese subgroup of patients, the reduction in mean percent pain relief over time was statistically significant (*P* = .002) (Appendix Table 1 and Table 2).

Table 1. Demographics and baseline information of the study population.

Variable	n
Total	132
Gender (%)	
Men	62 (47%)
Women	70 (53%)
SCS Therapy (%)	
Standard	59 (45%)
HF10	73 (55%)
Complications (%)	41 (32%)
Revisions (%)	24 (18%)
Explants (%)	18 (14%)
Indications (%)	
Chronic Regional Pain (CRPS)	10 (7%)
Failed Back Surgery Syndrome (FBSS)	6 (4%)
Lumbar Radiculopathy (LR)/Cervical Radiculopathy (CR)	16 (12%)
Post Laminectomy Syndrome (PLS)	82 (62%)
Neuralgia	8 (6%)
OTHER (e.g., Central Pain Syndrome, Chronic angina, fibromyalgia)	10 (7%)
Mean Age (SD)	55.6 (13.2)
Mean BMI (SD)	29.2 (7.1)
Normal (18.5-24.9)	29.2 (7.1)
Overweight (25.0-29)	46 (35%)
Obesity (> 30.0)	44 (33%)

Abbreviations: BMI, body mass index; SCS, spinal cord stimulation; SD, standard deviation

### Percentage of Responders

It is important to elaborate more on the percentage of responders (patients getting more than or equal to 50% pain relief with respect to baseline pain) to better understand the therapeutic effect. During the trial, 82% of the study population reported a 50% or more reduction in NPS. However, at one month, responders represented 44% of the study population, followed by 40% and 33% at 6 months and one year, respectively. Thus, in this study cohort, the percentage of patients getting more than 50% pain relief decreased by 11% at one year as compared to one month (Fig. 3). Only a 6% decrease in the percentage of pain responders was seen in the HF10 SCS group compared to the 15% decrease in the standard SCS group, from one month to one year post implant. There was an almost equal decrease in percentage of responders in men and women. Moreover, a greater

Table 2. NPS changes in the study cohort over time.

Time	Baseline	1 mo	6 mos	1 y
n	132	129	114	97
Mean NPS	8.4	4.7	4.7	4.9
Standard Deviation (SD)	1.11	1.98	2.08	2.05
Standard Error Mean (SEM)	0.09	0.17	0.19	0.20
P value		< .001	< .001	< .001
95% Confidence Interval		3.34 - 4.05	3.20 - 4.09	3.05 - 3.99

Abbreviations: NPS, Numeric Pain Score

decrease in the percentage of responders among patients less than 56 years of age was also noted over time. An interesting observation was that of an increase in the percentage of responders in the normal and overweight subgroups between one month and one year post implant. However, in obese patients, there was a substantial decrease in the percentage of responders, from 52% at one month to 29% at one year post implant (Fig. 4).

### Complications

A total of 41 cases of complications were reported among the 132 patients in the study, and sometimes patients experienced more than one complication" (Table 3). "Inadequate pain relief" (described as tolerance or loss of therapeutic effect despite appropriate stimulation coverage that cannot be explained by a hardware-related issue) along with "implantable pulse generator (IPG) site pain" were the most common complications associated with the HF10 SCS system, seen in 23% of cases. "SCS malfunction" (17%) was most commonly associated with standard SCS devices. SCS system malfunction involves either of the following: lead migration, lead defect/fracture, or IPG battery issue or other hardware-related complication. It was noted that such hardware-related complications were more common than biologic complications and a prominent issue with SCS that required revisions. Inadequate pain relief was seen in 13 patients (10%) and accounted for 76% of explants.

### Revisions and Explants

There were 24 revisions and 18 explants in 132 patients, for a revision rate and explant rate of 18% and 14%, respectively. Indications for revision in order of decreasing frequency included IPG site pain, SCS system

malfunction (involving either leads migration/defect or IPG battery issue), and loss of therapeutic effect/inadequate pain relief. Indications for explant in this patient population, in order of decreasing frequency, included loss of therapeutic effect, IPG discomfort/site pain, and SCS malfunction related to migration, IPG battery defect, etc. As shown in Appendix Fig. 2, the device retention rate was 53% at the end of 3 years, which included all those patients who continuously used the SCS device and hadn't yet undergone a revision or explant.

**DISCUSSION**

This study demonstrates the effectiveness of SCS therapy in a challenging clinical patient cohort and demonstrates significant improvements in pain and patient satisfaction. The results signify a promising therapeutic option for patients suffering from a range of chronic intractable pain conditions who have previously failed conservative treatment. Efficacy of traditional low-frequency SCS may diminish with time, as seen in this study as well as other studies in the literature (7,19). It is essential to evaluate any new SCS modality over a longer term. Additionally, this is one of the few studies to provide 12-month follow-up information related to efficacy, patient satisfaction, and safety data of patients who have undergone a HF10 SCS implant. Other strengths of the study include the fact that it is one of the few studies to assess the association of sociodemographic characteristics with pain outcomes in SCS patients, its sizeable study group for the new SCS modality (73 patients receiving permanent HF10 SCS implant), and a high follow-up percentage of 86% (63 of 73) at 12 months for the HF10 subgroup of patients.

**Pain Score Outcomes**

Pain significantly declined, as seen by the NPS at 6- and 12-months post implant, whether observing all patients or patient subgroups based on age, gender, therapy, and BMI. The results of this study are similar to several other clinical studies (9,13,15). The average NPS scores decreased by more than 50% in 82% of the study population during the trial, which was sustained by only 33% of the total study population at one year. The percentage of responders was similar among both the HF10 and traditional SCS therapy patients at the end of one year. The results in this study add to the evidence that the benefits of SCS diminish over time. According to the chart review of the study population,




Fig 1. Mean percent pain relief (PPR) between the 2 types of SCS therapy and overall study population over time.



Fig 2. Comparing mean percent pain relief (PPR) at 1 month and 1 year within a group.

\*the decrease in mean PPR for male population at one month (44%) as compared to one year (38%) is statistically significant ( $P = .02$ )

^ In obese patients decrease in Mean PPR with time is statistically significant ( $P = .002$ ).



Fig 3. Percent responders\* across time in the study population and according to the SCS therapy.

\*patients getting more than or equal to 50% pain relief with respect to baseline pain.




Fig 4. Percent responders\* across time according to demographic groups.  
 \*patients getting more than or equal to 50% pain relief with respect to baseline pain

Table 3. Summary of complications related to SCS in the study population.

Complications	No. of Cases		
	STD (n = 59)	HF10 (n = 73)	Total (n = 132)
IPG site pain	4 (7%)	9 (12%)	13 (10%)
SCS malfunction	10 (17%)	2 (3%)	12 (9%)
Inadequate pain relief	5 (8%)	8 (11%)	13 (10%)
Infection	2 (3%)	1 (1%)	3 (2%)

Abbreviations: IPG, implantable pulse generator; SCS, spinal cord stimulation; STD, standard SCS

the following reasons may be responsible for lack of significant pain relief: confounding pathology (new and/or old), progression of disease, patients reframing their pain, low pretrial NPS scores, trial success based on benefits other than pain, device troubleshooting and programming issues, and infection.

Interesting results were observed when mean percent pain relief was compared among various subgroups based on sociodemographic characteristics. In the normal and overweight subgroups of patients, the mean percent pain relief as well as the percentage of responders increased with time. Statistically significant decreases in pain relief over time among men and in the obese subgroup of patients were observed. There is a possibility that SCS therapy is not advisable for these 2 subgroups in

the long run as treatment efficacy reduces with time and thus SCS may not prove to be a cost-effective alternative compared to standard treatment in such cases. The probable causes behind this finding need further prospective research, and the associations between gender, BMI, and pain relief with SCS should be studied in greater detail with a bigger sample in a clinical trial.

### Traditional SCS vs. HF10 Therapy

From this study, it can be concluded that HF10 therapy potentially demonstrates greater long-term efficacy and safety. A study by Al-Kaisy et al (15) found that using HF10 SCS in patients who have failed traditional SCS has long-term benefits. These patients had either failed an SCS trial due to the lack of back paresthesia coverage or failed after permanent IPG implant due to the loss of back pain relief. This is particularly important for many patients with current SCS systems who are not getting optimal results. One major advantage of HF10 SCS therapy is that it overcomes the paresthesia effect. It is important to further study how different HF10 SCS parameters contribute to the modulation of neural pathways responsible for nociception in order to better understand the differences in efficacy and safety of the 2 types of SCS therapies.

### Complications

The complications of SCS can be many and the incidence reported in the current study population was 32%,

which is within the reported incidences of 30% to 55% in multiple studies (5,20-22). But the revision and explant rates noted in this cohort were less than incidences reported in other studies (23). It is important to recognize patterns that may help the practitioner prevent, predict, and manage these complications. With the majority of explants being secondary to “inadequate pain relief” in this study cohort, further research into the identification of causative factors and development of management strategies are important to maintain the long-term efficacy of SCS. Our goal will be to identify ahead of time patients who would not get adequate relief and to avoid implanting them in the first place.

Hardware-related problems such as lead/IPG failure and migration were more common than biological complications including infection, pain, and wound breakdown. The high rates of hardware-related complications could be improved significantly with the recent advancement of SCS technology. Infection is one of the major complications of SCS and is a common cause for device removal according to previous studies. The incidence of infection was 2% in this cohort, which is less than the range of 4% to 10% published in the literature (20-22,24,25). The pain center’s extensive experiences in these procedures, strict sterile technique, reduction in surgical time, perioperative prophylactic antibiotic therapy, and close postoperative follow-up could be some of the reasons for minimal incidences of infection and other complications.

### **Limitations and Future Studies**

Documentation of outcomes and patient follow-up was less rigorous in this study as compared to clinical trials, and missing data is unavoidable in a retrospective study design. A portion of patients were also lost

to follow-up and could potentially bias the outcome in either a positive or negative way. For example, if a patient is doing well, they may not feel the need to attend follow-up sessions, resulting in underreporting of successful clinical outcomes; alternatively, nonresponders to treatment may not feel better and seek alternative follow-up care elsewhere. Another limitation is regarding the heterogeneity of the patient population, such as the wide range of pain distributions, underlying indications/diagnoses, and the presence of comorbidities that may confound reported pain outcomes.

Currently, gaps exist in reporting complete information on stimulation parameters, mechanism of action of SCS devices, and safety outcomes, all of which may be improved through standardization of reporting. Furthermore, studies should report on the long-term outcomes in SCS as well as compare different types of SCS treatment modalities.


### **CONCLUSION**

Repeated evaluation regarding patient outcomes in terms of pain control, any complications, and overall satisfaction is essential to compare and maintain different SCS therapies in clinical practice. It is important to continuously analyze efficacy of HF10 SCS therapy through postmarket “real world” studies. A statistically significant decrease in pain relief with time was observed in men and obese patients. Thus, association of long-term pain relief related to gender and obesity in SCS patients needs further investigation. The current study provides promising evidence that both modalities of SCS are viable alternatives for patients with chronic intractable pain conditions in a standard clinical practice setting.


## REFERENCES

1. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. *Pain Suppl* 1986; 3:S1-S226.
2. Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: A World Health Organization study in primary care. *JAMA* 1998; 280:147-151.
3. Compton AK, Shah B, Hayek SM. Spinal cord stimulation: A review. *Curr Pain Headache Rep* 2012; 16:35-42.
4. Kunnumpurath S, Srinivasagopalan R, Vadivelu N. Spinal cord stimulation: Principles of past, present and future practice: a review. *J Clin Monit Comput* 2009; 23:333-339.
5. Cameron T. Safety and efficacy of spinal cord stimulation for the treatment of chronic pain: A 20-year literature review. *J Neurosurg* 2004; 100:254-267.
6. Kumar K, Taylor RS, Jacques L, et al. Spinal cord stimulation versus conventional medical management for neuropathic pain: A multicentre randomised controlled trial in patients with failed back surgery syndrome. *Pain* 2007; 132:179-188.
7. Kumar K, Taylor RS, Jacques L, et al. The effects of spinal cord stimulation in neuropathic pain are sustained: A 24-month follow-up of the prospective randomized controlled multicenter trial of the effectiveness of spinal cord stimulation. *Neurosurgery* 2008; 63:762-770; discussion 770.
8. Song JJ, Popescu A, Bell RL. Present and potential use of spinal cord stimulation to control chronic pain. *Pain Physician* 2014; 17:235-246.
9. Van Buyten J-P, Al-Kaisy A, Smet I, Palmisani S, Smith T. High-frequency spinal cord stimulation for the treatment of chronic back pain patients: Results of a prospective multicenter European clinical study. *Neuromodulation* 2013; 16:59-65; discussion 65-66.
10. Tiede J, Brown L, Gekht G, Vallejo R, Yearwood T, Morgan D. Novel spinal cord stimulation parameters in patients with predominant back pain. *Neuromodulation* 2013; 16:370-375.
11. Schultz DM, Webster L, Kosek P, Dar U, Tan Y, Sun M. Sensor-driven position-adaptive spinal cord stimulation for chronic pain. *Pain Physician* 2012; 15:1-12.
12. Kapural L, Yu C, Doust MW, et al. Comparison of 10-kHz high-frequency and traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain: 24-month results from a multicenter, randomized, controlled pivotal trial. *Neurosurgery* 2016; 79:667-677.
13. Russo M, Verrills P, Mitchell B, Salmon J, Barnard A, Santarelli D. High frequency spinal cord stimulation at 10 kHz for the treatment of chronic pain: 6-month Australian clinical experience. *Pain Physician* 2016; 19:267-280.
14. Kapural L, Yu C, Doust MW, et al. Novel 10-kHz high-frequency therapy (HF10 therapy) is superior to traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain: The SENZA-RCT randomized controlled trial. *Anesthesiology* 2015; 123:851-860.
15. Al-Kaisy A, Van Buyten J-P, Smet I, Palmisani S, Pang D, Smith T. Sustained effectiveness of 10 kHz high-frequency spinal cord stimulation for patients with chronic, low back pain: 24-month results of a prospective multicenter study. *Pain Med* 2014; 15:347-354.
16. de Vos CC, Dijkstra C, Lenders MW, Holsheimer J. Spinal cord stimulation with hybrid lead relieves pain in low back and legs. *Neuromodulation* 2012; 15:118-123; discussion 123.
17. Kumar K, Hunter G, Demeria D. Spinal cord stimulation in treatment of chronic benign pain: Challenges in treatment planning and present status, a 22-year experience. *Neurosurgery* 2006; 58:481-496; discussion 481-496.
18. Barolat G, Oakley JC, Law JD, North RB, Ketcik B, Sharan A. Epidural spinal cord stimulation with a multiple electrode paddle lead is effective in treating intractable low back pain. *Neuromodulation* 2001; 4:59-66.
19. Kemler MA, de Vet HCW, Barendse GAM, van den Wildenberg FAJM, van Kleef M. Effect of spinal cord stimulation for chronic complex regional pain syndrome Type I: Five-year final follow-up of patients in a randomized controlled trial. *J Neurosurg* 2008; 108:292-298.
20. Mekhail NA, Mathews M, Nageeb F, Guirguis M, Mekhail MN, Cheng J. Retrospective review of 707 cases of spinal cord stimulation: Indications and complications. *Pain Pract* 2011; 11:148-153.
21. Turner JA, Loeser JD, Deyo RA, Sanders SB. Spinal cord stimulation for patients with failed back surgery syndrome or complex regional pain syndrome: A systematic review of effectiveness and complications. *Pain* 2004; 108:137-147.
22. Kumar K, Wilson JR, Taylor RS, Gupta S. Complications of spinal cord stimulation, suggestions to improve outcome, and financial impact. *J Neurosurg Spine* 2006; 5:191-203.
23. Hayek SM, Veizi E, Hanes M. Treatment-limiting complications of percutaneous spinal cord stimulator implants: A review of eight years of experience from an academic center database. *Neuromodulation* 2015; 18:603-609.
24. Turner JA, Loeser JD, Bell KG. Spinal cord stimulation for chronic low back pain: A systematic literature synthesis. *Neurosurgery* 1995; 37:1088-1095; discussion 1095-1096.
25. Kay AD, McIntyre MD, Macrae WA, Varma TRK. Spinal cord stimulation – A long-term evaluation in patients with chronic pain. *Br J Neurosurg* 2001; 15:335-341.





Appendix Fig 1. Follow up information about the study population.



Appendix Fig 2. Correlation of revision and explants (as events) over time with Kaplan Meir graph.

Appendix Table 1. Comparing mean percent pain relief at 1 month and 1 year within a sub-group.

GROUP	Mean Pain % relief at Trial	Mean Pain % relief at 1 month	Mean Pain % relief at 1 year	P Value
<b>Therapy</b>				
STD (n = 45)	70	46	44	0.30
HF10 (n = 52)	67	43	40	0.56
<b>Gender</b>				
Men (n = 48)	67	44	38	<b>0.02</b>
Women (n = 49)	70	44	43	0.99
<b>Age</b>				
≤ 55 years (n = 46)	70	44	39	0.24
> 55 years (n = 51)	68	43	41	0.58
<b>BMI</b>				
Normal (n = 23)	69	40	43	0.73
Overweight (n = 33)	68	43	44	0.69
Obese (n = 34)	67	47	36	<b>0.002</b>

Appendix Table 2. Comparing mean percent pain relief (PPR) over time between the sub-groups.

GROUP		Trial	1 month	6 months	1 year
<b>Therapy</b>					
HF10 SCS	n	73	70	61	52
	Mean PPR (SD)	66.9 (13.01)	42.6 (20.3)	42 (25.6)	39.8 (22.7)
STD SCS	n	59	58	52	45
	Mean PPR (SD)	70 (11.8)	45.7 (22.2)	46.3 (22.4)	43.8 (27)
	<b>P value</b>	<b>0.15</b>	<b>0.43</b>	<b>0.35</b>	<b>0.45</b>
<b>Gender</b>					
Men	n	62	62	56	48
	Mean PPR (SD)	67.7 (10.8)	44.5 (20.9)	42.6 (26.6)	38.4 (23.8)
Women	n	70	67	58	49
	Mean PPR (SD)	68.8 (13.4)	42.9 (22)	44.6 (22.2)	43.2 (26.6)
	<b>P value</b>	<b>0.6</b>	<b>0.69</b>	<b>0.67</b>	<b>0.36</b>
<b>Age</b>					
≤ 55 years	n	65	63	58	46
	Mean PPR (SD)	69.8 (10.8)	45 (23.5)	46.6 (27.5)	42.6 (26.5)
> 55 years	n	67	66	59	51
	Mean PPR (SD)	66.8 (13.3)	41.1 (19.3)	43.5 (23.9)	43.7 (28.1)
	<b>P value</b>	<b>0.16</b>	<b>0.49</b>	<b>0.52</b>	<b>0.84</b>
<b>BMI</b>					
Normal	n	32	32	26	24
	Mean PPR (SD)	69.1 (11.8)	40.09 (23.7)	46.6 (26.0)	43.3 (26.7)
Overweight	n	46	44	39	33
	Mean PPR (SD)	68.5 (13.2)	43.4 (22.1)	43.4 (22.6)	44 (24.4)
Obese	n	44	44	40	34
	Mean PPR (SD)	66.9 (11.5)	46.7 (22.0)	41.9 (26.8)	35.9 (24.0)
	<b>P value</b>	<b>0.72</b>	<b>0.44</b>	<b>0.75</b>	<b>0.35</b>